Mereo BioPharma (MREO) Cash & Equivalents (2017 - 2026)

Mereo BioPharma (MREO) has reported Cash & Equivalents for 10 consecutive years, with $36.2 million the latest figure, recorded in Q1 2026.

• Quarterly Cash & Equivalents fell 42.04% year-over-year to $36.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $36.2 million (down 42.04% YoY) and the FY2025 annual result came in at $41.0 million, down 41.27% from the prior year.
• Cash & Equivalents fell to $36.2 million in Q1 2026 per MREO's latest filing, from $41.0 million in the prior quarter.
• Over the last five years, Cash & Equivalents for MREO reached as high as $96.2 million in Q2 2022 and fell as low as $36.2 million in Q1 2026.
• A 5-year average of $61.8 million and a median of $57.4 million in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents sank 48.02% — and 2024, when it soared 65.91%.
• Year by year, Cash & Equivalents stood at $66.1 million in 2022, then fell by 13.1% to $57.4 million in 2023, then grew by 21.56% to $69.8 million in 2024, then slumped by 41.27% to $41.0 million in 2025, then slipped by 11.63% to $36.2 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $36.2 million, $41.0 million, and $48.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.